

Japan Diabetes Drugs and Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2018 - 2029

Market Report | 2024-02-17 | 70 pages | Mordor Intelligence

AVAILABLE LICENSES:

- Single User License \$4750.00
- Team License (1-7 Users) \$5250.00
- Site License \$6500.00
- Corporate License \$8750.00

Report description:

Japan's Diabetes Care Drugs and Devices Market size is estimated at USD 11.5 billion in the current year. The market is expected to reach USD 13.5 billion in five years, registering a CAGR of more than 3.2% during the forecast period.

The COVID-19 pandemic has had a significant impact on the diabetes drug market. Due to the prevalence of diabetes in patients hospitalized with COVID-19 and the recognition that improved glycemic control may improve outcomes and shorten hospital stays in patients with SARS-CoV-2, diabetes treatment The importance of equipment is emphasized. At the American Diabetes Association's (ADA) 81st Virtual Scientific Meeting, a retrospective analysis showed that diabetes is the leading risk factor for accelerated severity of COVID-19 infection among Japanese.

Diabetes remained a major risk factor for COVID-19 throughout the pandemic. A malfunction of the immune system causes type 1 diabetes, whereas type 2 diabetes is associated with a sedentary lifestyle, leading to congenital insulin resistance. Therefore, type 1 diabetes can be characterized as insulin-dependent diabetes, and type 2 diabetes can be characterized as insulin-dependent diabetes. Japan has one of the largest elderly populations in the world and is more prone to developing type 2 diabetes. In Japan, the population is aging, and the prevalence of diabetes is increasing. Blood sugar levels are increasingly monitored and controlled to avoid adverse effects such as cardiovascular disease, kidney disease, etc.

Thus, the above factors are expected to drive market growth over the forecast period.

Japan Diabetes Drugs and Devices Market Trends

The continuous Glucose Monitoring Segment is Expected to Witness the Highest Growth Rate Over the Forecast Period

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott-international.com

www.scott-international.com

The continuous glucose monitoring segment is expected to register a CAGR of more than 11% over the forecast period.

Continuous glucose monitoring sensors use glucose oxidase to measure blood sugar levels. Glucose oxidase converts glucose to hydrogen peroxide, which reacts with platinum in the sensor to produce an electrical signal sent to a transmitter. The sensor is the most important part of any continuous blood glucose monitoring device. Researchers seek to find and develop alternatives to electrochemical glucose sensors to make CGM sensors more affordable, minimally invasive, and user-friendly. Optical measurement is a promising platform for glucose measurement. Several techniques with high potential for continuous glucose measurement have been reported, including spectroscopy, fluorescence, and holographic techniques. Eversense, a fluorescence based CGM sensor developed by Sensoics Company, has a much longer lifetime than electrochemical sensors. Technological advances in improving sensor accuracy are expected to drive the growth of the segment during the forecast period. With CGM, a small sensor is inserted into the abdomen or arm using a small plastic cannula that penetrates the top layer of the skin. An adhesive patch holds the sensor in place, allowing it to measure glucose levels in interstitial fluid day and night. In general, the sensor should be replaced every 7-14 days. A small, reusable transmitter attached to the sensor allows the system to wirelessly transmit real-time readings to a monitor displaying blood glucose data. Some systems have their own monitor, while others show information via smartphone apps.

The frequency of monitoring blood glucose levels depends on the type of diabetes and is different for each patient. Patients with type 1 diabetes should monitor their blood sugar levels with regular checks and adjust their insulin dosage accordingly. His CGM device now details blood glucose patterns and trends compared to routine blood glucose monitoring at set intervals. In addition, current continuous blood glucose monitors can retroactively check blood glucose trends by downloading data or providing real-time images of blood glucose levels via the receiver display. New technologies like cell phone integration make continuous glucose monitoring devices increasingly affordable. This is likely to drive the growth of the segment during the forecast period.

Rising diabetes prevalence

Diabetes is classified as an important health problem by the Ministry of Health, Labor and Welfare. The high prevalence of type 2 diabetes comes with a significant economic burden. The cost of diabetes increases in patients with comorbidities such as hypertension and hyperlipidemia and those who develop complications. As the number of complications increases, so does the price. In Japan, a well-developed health insurance system covers all medical expenses for diabetes, and people with diabetes can see a doctor for free. Insulin self-injection therapy has also been legalized and covered by health insurance companies. These advantages have led to introducing of these products into the Japanese market.

Oral antidiabetic agents are available worldwide and are recommended for use when lifestyle management and escalation of type 2 diabetes treatment are required. Oral formulations are usually the drugs of first choice for the treatment of type 2 diabetes because of their wide range of efficacy, safety, and mechanisms of action. Antidiabetic drugs help people with diabetes control their condition and reduce the risk of diabetic complications. People with diabetes may need to take antidiabetic drugs throughout their lives to control blood sugar levels and avoid hypoglycemia or hyperglycemia. Oral hypoglycemic agents have the advantage of being easy to use and inexpensive. This has made them an attractive alternative to insulin, leading to greater acceptance and improved adherence. In Japan, the prevalence of diabetes is increasing in all age groups due to a growing obese population, unhealthy diets, and sedentary lifestyles. Diabetes is a significant concern due to its high prevalence and increasing financial burden on clinical systems, individuals, and governments. The Japanese healthcare system includes several disease control programs run by the Japan Diabetes Education and Care Association. Japan is one of the leaders in the Asia-Pacific region when it comes to public health policy for people with diabetes. The country is raising public awareness and implementing preventive measures focused on lifestyle and dietary changes that can reduce the likelihood of adult-onset diabetes.

The increasing diabetes prevalence and the above factors will likely drive segment growth over the forecast period.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Japan Diabetes Drugs and Devices Industry Overview

Large companies such as Abbott and Medtronic have made numerous mergers, acquisitions, and partnerships to gain market dominance while adhering to organic growth strategies. The manufacturers of insulin delivery devices are spending a huge amount on the R&D of the devices. For example, Novo Nordisk partnered with Abbott Diabetes Care, which may also assist to enable insulin statistics to be shared between Novo Nordisk-connected insulin pens and digital fitness equipment well suited to the FreeStyle Libre portfolio of products.

Additional Benefits:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

Table of Contents:

1 INTRODUCTION

- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

- 4.1 Market Overview
- 4.2 Market Dynamics
 - 4.2.1 Market Drivers
 - 4.2.2 Market Restraints
- 4.3 Porter's Five Forces Analysis
 - 4.3.1 Bargaining Power of Suppliers
 - 4.3.2 Bargaining Power of Consumers
 - 4.3.3 Threat of New Entrants
 - 4.3.4 Threat of Substitute Products and Services
 - 4.3.5 Intensity of Competitive Rivalry

5 Market Segmentation (Market Size by Value - USD)

- 5.1 Devices
 - 5.1.1 Monitoring Devices
 - 5.1.1.1 Self-monitoring Blood Glucose Devices
 - 5.1.1.2 Continuous Blood Glucose Monitoring
 - 5.1.2 Management Devices
 - 5.1.2.1 Insulin Pump
 - 5.1.2.2 Insulin Syringes
 - 5.1.2.3 Insulin Cartridges
 - 5.1.2.4 Disposable Pens
- 5.2 Drugs
 - 5.2.1 Oral Anti-Diabetes Drugs

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.2.2 Insulin Drugs
- 5.2.3 Combination Drugs
- 5.2.4 Non-Insulin Injectable Drugs

6 Market Indicators

- 6.1 Type-1 Diabetes Population
- 6.2 Type-2 Diabetes Population

7 COMPETITIVE LANDSCAPE

7.1 Company Profiles

- 7.1.1 Novo Nordisk
 - 7.1.2 Medtronic
 - 7.1.3 Insulet
 - 7.1.4 Tandem
 - 7.1.5 Ypsomed
 - 7.1.6 Novartis
 - 7.1.7 Sanofi
 - 7.1.8 Eli Lilly
 - 7.1.9 Abbott
 - 7.1.10 Roche
 - 7.1.11 Astrazeneca
 - 7.1.12 Dexcom
 - 7.1.13 Pfizer
- ### 7.2 Company Share Analysis

8 MARKET OPPORTUNITIES AND FUTURE TRENDS

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Japan Diabetes Drugs and Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2018 - 2029

Market Report | 2024-02-17 | 70 pages | Mordor Intelligence

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4750.00
	Team License (1-7 Users)	\$5250.00
	Site License	\$6500.00
	Corporate License	\$8750.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-02"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

